e-santé : Livia (Israël) un dispositif révolutionnaire pour calmer les règles douloureuses

[:fr]Plus de 50% de femmes dans le monde souffrent de douleurs menstruelles, avec une forte altération de la qualité de vie et un sentiment de fatalisme difficilement supportable. Aussi le lancement de Livia, un dispositif e-santé révolutionnaire, est-il très attendu par les femmes qui recherchent un soulagement non pharmaceutique aux crampes menstruelles. Lorsque les journalistes féminines de Cosmopolitan, Seventeen ou HuffPost ont ouvert les colis contenant le dispositif portable Livia destiné à soulager les douleurs menstruelles, elles ignoraient qu’il avait été inventé par deux israéliens, père et fils.

Ce dispositif, dénommé Livia, a créé le buzz dans le monde entier et a recueilli plus de 300 000 $ de soutiens à ce jour lors de la campagne de crowdfunding Indiegogo lancée avec un objectif initial de 50000 $.

iPulse médical, la compagnie israélienne basée à Raanana qui a lancé Livia, a été fondée en avril 2015 et est dirigée par Chen Nachum, célibataire de 36 ans. «Cette technologie a été inventée par mon père, Zvi Nachum, mais de nombreuses femmes ont participé à son designing » précise Chem Nachum.
Zvi Nachum, qui a déjà déposé plusieurs brevets dans le domaine médical, cherchait à développer des solutions pour calmer la douleur dans le cadre d’un projet différent et a découvert par hasard comment affiner la fréquence et l’onde d’une technologie existante appelée TENS (stimulation nerveuse électrique transcutanée) pour bloquer des types spécifiques de douleurs.

Plus de 50% des femmes souffrent de crampes menstruelles primaires, pour lesquelles elles consomment de grandes quantités d’analgésiques. Livia utilise une méthode de soulagement de la douleur qui exclue la consommation de drogues. L’idée est de fermer la «porte de la douleur ». Le dispositif dispose d’une autonomie de 15 heures et stimule les nerfs, ce qui rend impossible à la douleur de passer. La méthode Livia aurait prouvé son efficacité lors de plusieurs études cliniques.

En cours d’obtention des agréments FDA et CE, Livia a été cliniquement testé sur 163 femmes par le Dr Bari Kaplan à l’Hôpital Rabin Medical Center à Petah Tikva. Il devrait être commercialisé au prix de 150$ en octobre prochain. Les inventeurs espèrent réduire le coût de fabrication.
Source israel21c[:en]The launch of Livia is eagerly awaited by women across the globe looking for non-narcotic relief from menstrual cramps. When female reporters from publications including Cosmopolitan, Seventeen and HuffPost opened packages containing a wearable device to relieve menstrual pain, they probably didn’t realize it was invented by an Israeli father and son.

But that odd fact didn’t really matter. The device, called Livia,  has created a buzz worldwide and has garnered more than $300,000 from supporters so far in an Indiegogo crowdfunding campaign  launched with a $50,000 goal.

iPulse Medical, the company behind Livia, was founded in April 2015 and is headed by Chen Nachum, a 36-year-old bachelor.
“The technology is my father’s,” Nachum tells ISRAEL21c.

Zvi Nachum, a medical patents developer, was experimenting with pain solutions for a different project and discovered how to fine-tune the frequency and wave shape of an existing technology called TENS (transcutaneous electrical nerve stimulation) to block specific types of pain.

“But that wasn’t his original project, so he put it aside and I took over,” says Nachum.

Nachum gathered a mostly female group of Israeli experts to birth Livia: industrial designers from Tenenbaum Hazan Design Studio in Herzliya, marketing and branding gurus from Tross Creative in Tel Aviv, and publicists from Blonde 2.0 in Tel Aviv. It was the publicists who had the idea of 3D-printing 20 prototypes to send to influential women journalists.

Over 50% of women suffer primary menstrual cramps, for which they consume large amounts of painkillers. Livia uses a pain relief method that does not involve drug consumption. The idea is to close the « pain gates ». The device stimulates the nerves, making it impossible for pain to pass. The method Livia uses has been proven effective in several clinical studies and I strongly recommend the use of the device to relieve PMS at any time.

Livia’s product design was handled by a mostly female team at Tenenbaum Hazan Design Studio, Herzliya. Photo courtesy of Livia

The result is a small patent-pending wearable (available in a variety of fun colors) that claims to provide nearly instant relief from cramps in three easy steps: attach the electrodes via gel pads to the spot where pain is worst, clip the device onto a waistband or pocket, and switch it on.

Livia lasts up to 15 hours on a single charge, doesn’t interfere with the menstrual cycle or hormonal balance, and provides a discreet natural alternative to pain pills and hot-water bottles.

Now nearing completion of the FDA and CE regulatory approval processes, Livia was clinically tested on 163 women by Dr. Bari Kaplan at the Women’s Hospital of Rabin Medical Center in Petah Tikva.

“Over 50 percent of women suffer primary menstrual cramps, for which they consume large amounts of painkillers,” said Kaplan, a male gynecologist. “Livia uses a pain-relief method that does not involve drug consumption. The idea is to close the ‘pain gates.’ The device stimulates the nerves, making it impossible for pain to pass. The method Livia uses has been proven effective in several clinical studies.”

Assembled in Israel, Livia devices are supposed to go on the market in October at an initial retail price of about $149, though Nachum hopes to reduce the cost as manufacturing becomes more streamlined.

“Especially with people looking into holistic alternatives for food, medicine, and other industries, Livia is the natural step to take in order to get relief from menstrual pain, especially for women whose cramps can really be debilitating,” says Nachum.
Based in Ra’anana, iPulse Medical has established a corporate presence for Livia in Delaware in anticipation of a lot of demand in the American market. The device is expected to sell worldwide.

Source israel21c[:]